1. Academic Validation
  2. Inhibition Molecular Mechanism of α2 Adrenergic Receptor Activation by Antagonist

Inhibition Molecular Mechanism of α2 Adrenergic Receptor Activation by Antagonist

  • FASEB J. 2025 Jun 15;39(11):e70624. doi: 10.1096/fj.202403409R.
Yiming Li 1 Haizhan Jiao 2 Hongli Hu 2 Yuyong Tao 1 Qiong Guo 1
Affiliations

Affiliations

  • 1 Department of Laboratory Medicine, the First Affiliated Hospital of USTC, MOE Key Laboratory for Membraneless Organelles and Cellular Dynamics, Hefei National Center for Cross-Disciplinary Sciences, Biomedical Sciences and Health Laboratory of Anhui Province, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • 2 Kobilka Institute of Innovative Drug Discovery, School of Medicine, the Chinese University of Hong Kong, Shenzhen, China.
Abstract

The α2A Adrenergic Receptor2AAR) and α2B Adrenergic Receptor2BAR) are G protein-coupled receptors (GPCRs) that mediate important physiological functions in response to the endogenous neurotransmitters norepinephrine and epinephrine. Antagonist drugs targeting α2ARs have been widely used for many years. However, current structural studies of drug-receptor complexes are insufficient to elucidate their interactions. Here, to uncover the molecular mechanisms of antagonist drug actions, we determine the cryo-electron microscopy (cryo-EM) structures of α2AAR bound to phentolamine and α2BAR bound to phenoxybenzamine. Together with the mutagenesis data, these results provide insights into the molecular basis of ligand recognition and antagonism at α2AAR and α2BAR. Overall, our studies contribute to a deeper understanding of Adrenergic Receptor modulation and provide some clues for the development of novel antagonists.

Keywords

GPCR; cryo‐EM structure; α2A adrenergic receptor; α2B adrenergic receptor.

Figures
Products